Deutsche Märkte schließen in 5 Stunden 15 Minuten

Moderna, Inc. (MRNA)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
171,18-0,63 (-0,37%)
Börsenschluss: 04:00PM EDT
171,08 -0,10 (-0,06%)
Vorbörslich: 06:15AM EDT

Yahoo Finanzen Deutschland wird unser Diskussionsforum am 15. August entfernen. Vielen Dank, dass Sie so ein treues Mitglied unserer Diskussions-Community auf Yahoo Finanzen sind!

Melden Sie sich an, um eine Nachricht zu posten.
  • J
    Jay
    $SOFI conversation
    We can count on a beautiful market pump all the way to NOVEMBER

    ENJOY THE RIDE AND KEEP LOADING SHARES & CALLS

    HEAVY IN SOFI $TLRY $FUBO $COIN $MRNA
  • S
    Sell The News
    $NVAX conversation
  • B
    Bryan
    Moderna, Inc.
    This company has saved millions of lives. Go $MRNA!
  • N
    Nubbley
    $JNJ conversation
    in before the CDC shorts $JNJ $MRNA $PFE
  • S
    Sam
    $BNTX conversation
    I was waiting for some time now to buy some $bntx & $mrna. Thank you shorts for lowering the price! Just got in: 75% bntx, and 25% mrna. Good luck to you all!
  • S
    Senior Clown
    $NVAX conversation
    NVAX came too late to the party, is not effective and has side effects, but you want to be like $MRNA
  • P
    Peter-1
    $SIGA conversation
    Buy and hold for next few years
    Next $mrna or $bntx

    $siga will cross $300 soon
  • X
    Xavier
    $MRNA conversation
    $MRNA working on a herpes simplex vaccine. Up to 80% of the world’s population could be affected by it. That would be amazing.
  • S
    Stark
    $BNTX conversation
    Best in class

    Safety? Post market surveillance will over time will the incidence of side effects compared to mRNA vaccines. The pre approval debate is over. So far however the numbers and reports are coming in favorable. Much less common vaccine side effects like fever, headache, myalgia, injection site soreness and swelling. More severe side effects will be determined in time. So far we are coming in at half the incidence for anaphylactic shock and myocarditis.
    SAFETY? Check

    Efficacy? As per all available data, our prototype vaccine offers higher efficacy vs the variants past , present and most likely future. Most virologists are convinced of that when all available data is reviewed. GMT titers comparable, other broad indicators hACe superior. Clinical data superior. Efficacy far superior in children, where the same adult dosage is used vs a watered down version of Pfizer. Bi valent vaccines by all companies are upcoming.
    Efficacy? Check

    Durability? Most comparisons end at a month. mRNA typically has a intense immune response and dramatically drops off . At 3 months any vaccine protection is gone. Forcing continuous reboosting over and over. Each time you risk side effects such as anaphylactic shock and myocarditis. In addition the fever and pain. The constant boosting leads to T cell exhaustion, original antigenic sin where the vaccine induced a immune response to its previous original virus, autoimmune reactions, unknown long term side effects, studies showing the vaccine increases clearance of the virus vs those who were never vaccinated. That’s part is devastating news.
    When going out beyond the 30 days clinical studies showing longer durability for Novavax .
    Durability? Check

    Boosters? I listened to the entire FDA and CDC committee meetings . CDC so positive on our vaccine and the benefits . Half the conference was discussing the deployment of the vaccine including boosters . It’s a process, IMO they want the available supply to go to the unvaccinated hold outs so the percentage of vaccinated is higher. It’s not if at all, it’s just when. Probably couple of weeks.

    Investment thesis is intact. Same as it’s always been.
    Will dominant the Covid market in time. It will completely replace the pediatric market. Dosage independent pediatric vaccine that actually works with low side effects vs a watered down vaccine without any clinical data that it does actually work.

    mRNA as a infectious disease platform has not met expectations. Dosage dependent and toxic. Flu mRNA will never reach the market and if it does will be a complete commercial failure. Dose had to be increased to 50 mcg to reach a comparable efficacy with the present Flu vaccine. This vaccine has low side effects, 1/10 the risk of anaphylactic shock, lowers the risk of myocardial events vs a toxic mRNA ? Crazy!
    Pushing that people will want for convenience as a combo. No sorry not that stupid.
    Novavax flu? Yea 40% higher efficacy with less side effects.

    Future? Future is a pan -corona virus universal vaccine that is AI enhanced. Once a year in a voluntary basis effective against all variants. Novavax only company that can do that.

    Future pipeline? Looking good we Matrix -M an adjuvant that is patented and in high demand . Rsv, malaria, EBV on and on .
    $mrna. $ bntx
    Nvax
  • A
    Al
    Novavax, Inc.
    There will be a shift; $MRNA and Pfizer will go down and NVAX will go up. As people will prefer to take NVAX vaccine over the mRNA vaccine. owning NVAX will be lucrative and is the right decision to make
  • A
    Al
    Novavax, Inc.
    It is different proven superior technology than $BNTX & $MRNA
  • i
    investfordummies
    $NVAX conversation
    Why the US gvt is buying $NVAX... even if not yet approved... and not $MRNA or $BNTX shots... They want $NVAX to produce ASAP... That's my reading.
  • i
    investfordummies
    $MRNA conversation
    188$ last resistance on $MRNA before flying
    $BNTX $NVAX
  • J
    Joyce
    Moderna, Inc.
    Unfortunately, I didn't feel it earlier $MRNA $VENA
  • i
    investfordummies
    $NVAX conversation
    Let's assume, you are a fund manager... And don't have any NVAX, you wanted to play it safe and wait for FDA

    1/ It just got approved by FDA for covid shots (and already approved worldwide)

    2/Market expects 26$ EPS for 2022

    3/Covid is not gone after 3 years... we are getting new variants worldwide daily

    4/NVAX data is strong vs variants...

    5/ The company has a lot of cash on its balance sheet (1.8 bn end of September)

    6/ $MRNA $BNTX $PFE $JNJ all sold for more than $50bn of covid products in 2021? (it's a guess, could anyone confirm) I found this on CNBC: "Pfizer expects $32 billion in Covid vaccine sales for 2022, while Moderna is forecasting at least $19 billion in sales."

    7/ Market cap of $NVAX is 5 bn

    SURE you tell your manager, I don't feel like buying

    If you don't buy this? Change job, don't you agree?

    I've very rarely seen such a cheap stock pharma/biotech on all metrics, with real products, producing cash and huge potential (of course to be confirmed)
  • i
    investfordummies
    $NVAX conversation
    Big guys prefer to pay for $MRNA ... waiting higher market cap and FDA approval... no problem... Happy to do the bridge :-)
  • F
    Frogs
    $SIGA conversation
    Shades of $MRNA 2 years ago.
    Massive upside action. 🐒
  • i
    investfordummies
    $NVAX conversation
    Are $PFE $MRNA $BNTX down with this $NVAX rumor?
  • i
    investfordummies
    $NVAX conversation
    What is the risk that any big pharma like $PFE $JNJ buys $NVAX $BNTX $MRNA outright?

    Now they all have covid shots approved $NVAX since yesterday
    They all have a lot of cash on their balance sheet
    And are trading at 2022 PE of about 2 (ex-cash) for $NVAX and in any case much lower than 5 for all the 3 names...

    Anyone?
  • S
    Superman
    $MRNA conversation
    The FDA has approved Novavax for Adult use in the US. I invest in both $MRNA and $NVAX - hope to see a quick recovery for both starting today. A great step for a great company.